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The efficacy of topical human amniotic membrane-mesenchymal stem cell-
conditioned medium (hAMMSC-CM) and a mixture of topical hAMMSC-
CM + vitamin C and hAMMSC-CM + vitamin E on chronic plantar ulcers 
in leprosy: A randomized control trial 
ABSTRACT 
Background: Healing of chronic plantar ulcers in leprosy (CPUL) typically 
takes a long time due to impaired neurological function, thereby reducing the 
levels of growth factors and cytokines. Cytokines can be found in metabolite 
products from amniotic membrane stem cells. Chronic ulcers are frequently 
characterized by high levels of reactive oxygen species. Vitamin E (α-
tocopherol) is widely used in skin lesions, owing to its antioxidant and anti-
inflammatory properties. Vitamin C also has antioxidant, anti-inflammatory, 
and collagen synthesis properties useful in wound healing. Herein, we compared 
the effects of topical human amniotic membrane-mesenchymal stem cell-
conditioned medium (hAMMSC-CM) alone and with vitamins C and E on 
healing of CPUL. 
Methods: In this randomized controlled trial, topical agents were applied every 
3 days for up to 8 weeks. Ulcer size, side effects, and possible complications 
were monitored weekly. 
Results: Healing percentage increased each week in all groups. Mean difference 
in ulcer size was the highest in the hAMMSC-CM+vitamin E group, implying 
better progress of wound healing. There were no side effects or complications. 















Ulcers are defined as loss of continuity of skin tissue up to the dermis or deeper 
(subcutis). Approximately 30% of patients with leprosy have peripheral nerve damage, and 
10%–20% of them have neuropathic ulcers due to peripheral nerve damage. Leprosy ulcers 
are present mostly in plantar pedis, particularly in areas with bony prominence. The plantar 
pedis is a part of the body that functions in walking; thus, the risk of experiencing trauma is 
greater in this area than in other body parts [1–3]. Healing of plantar ulcers in leprosy often is 
difficult and time-consuming due to decreasing levels of growth factors and cytokines as a 
result of a prolonged inflammatory condition. The inflammatory condition can be caused by 
infection and ischemia due to persistent pressure on the wound from disruption of nerve 
functions. This causes obstruction of the wound healing process and formation of a chronic 
ulcer [4–8]. 
Since the early 20th century, amniotic membranes have been used to treat widespread 
injuries, burns, chronic and deep ulcers, and surgical wounds that are difficult to 
close. Studies on amniotic membrane stem cells for repair and regeneration of cells have 
shown good results. The production of growth factors and cytokines, which are required for 
tissue healing, is one of the mechanisms of stem cells in the tissue healing process. Growth 
factors and cytokines can be found in the tissue medium of stem cells in in vitro conditions 












Previous research has proven that injuries that are difficult to heal in humans are 
associated with high levels of oxidative stress. Wounds or chronic ulcers often show 
increasing levels of reactive oxygen species (ROS) or free radicals that can delay the wound 
healing process and inhibit formation of granulation tissue and epithelialization. Free radicals 
are formed in response to tissue damage and subsequently inhibit the recovery process by 
attacking DNA, membranes, proteins, and lipids from cells. Antioxidants are believed to 
repair wounds by reducing damage caused by free radicals released by neutrophils in the 
inflammatory phase of wound healing [15–17]. 
Prakoeswa et al. [18] compared the effects of topical human amniotic membrane-
mesenchymal stem cell-conditioned medium (hAMMSC-CM) and the framycetin gauze 
dressing (FGD) applied every 3 days for up to 8 weeks on healing of chronic plantar ulcers in 
leprosy (CPUL). Ulcer healing was significantly better in the hAMMSC-CM group than in 
the FGD group clinically and statistically (p < 0.005 and p < 0.005) [18]. 
The role of vitamin C, a known antioxidant, in collagen synthesis has believed to be 
useful in wound healing. As an antioxidant, vitamin C neutralizes ROS found in chronic 
ulcers. Vitamin C also directly stimulates collagen synthesis. Sodium ascorbyl phosphate 
(SAP) is a stable derivative of vitamin C [19–21]. 
Vitamin E is a nonenzymatic, natural antioxidant and the most important lipid soluble 
in human tissue that is absorbed well by the skin. Several studies have shown that vitamin E, 
particularly α-tocopherol, gives good results in the wound healing process. α-Tocopherol may 
serve as an antioxidant, reducing ischemic damage due to reperfusion disorders, and may 
stimulate growth and stabilize granulation tissue, as well as re-epithelialization [23,24]. 
In light of the aforementioned facts, the present study investigated the effect of topical 
gel hAMMSC-CM only (group 1) and a mixture of hAMMSC-CM + vitamin C (group 2) and 











Material and methods 
Study design and patients 
This experimental analytical randomized controlled clinical trial was performed using parallel 
designs in 22 subjects in each of the three treatment groups. Consecutive sampling was 
performed, i.e., we enrolled any patient with CPUL who met the criteria for admission 
samples at the Dermatology Venereology outpatient clinic,Dr Soetomo Teaching 
Hospital. The subjects were leprosy patients with CPUL of >6 weeks, an ulcer depth of <0.5 
cm, and a maximum injury area of 9 cm
2
 who did not consume systemic corticosteroids in the 
last 2 weeks. The subjects also had no history of diabetes mellitus, hemophilia, blood clotting 
physiological disorders, antiplatelet use, and hypersensitivity to transparent film dressings 
or adhesive plasters. This clinical study was approved by the ethical committee board of Dr. 
Soetomo Teaching Hospital Surabaya and was randomized with computerized and 
consecutive sampling. 
Treatment intervention 
Surgical debridement was performed in all groups before treatment to remove callus 
and necrotic tissue and return all ulcers to the same healing phase, i.e., the coagulation and 
inflammatory phase. The drug was applied every 3 days until the ulcer closed or for a 
maximum of 8 weeks. An extensive and deep ulcer measurement and evaluation of side 
effects and complications of both drugs were conducted weekly. Off-loading was not 
performed in any subject. Subjects were recommended only to reduce standing and walking 
activities. 
Laboratory testing 
Spectrophotometric examination was conducted using a spectrophotometer by 
measuring the absorbance at 280 nm to determine the total protein content per mL fluid 











used at 5.05 mg/mL. The hAMMSC-CM stability test was conducted in the laboratory testing 
unit of the Faculty of Pharmacy Universitas Airlangga for 4 weeks. The test was performed to 
determine the total protein content in hAMMSC-CM, which was [1.38 ± 0.1]% w/w on day 
one and [1.25 ± 0.02]% w/w on day 30. α-Tocopherol and SAP stability tests also were 
performed to determine the levels of α-tocopherol in groups 2 and 3. The α-Tocopherol 
content was measured weekly using high performance liquid chromatography for 4 
weeks. The α-tocopherol and SAP contents were [8.76% ± 0.1]% w/w on day 1 and [9.55% ± 
0.1]% w/w on day 30. The total protein and α-tocopherol contents of metabolites of stem 
cell products were relatively stable until week 4, and thus the product mix metabolite in 
groups 2 and 3 could be regenerated every 4 weeks, which were applied to the ulcer once 
every 3 days for a maximum of 8 weeks or 14 applications. 
Statistical analysis 
All enrolled patients were evaluated. The nonparametric Mann–Whitney U test was used to 
determine significant differences between samples before and after treatment within the same 
group and between two groups. P < 0.05 indicated statistical significance. All statistical 
analyses were performed using SPSS version 22.0 software (SPSS, Inc., Chicago, IL, USA).  
Results 
The patients were divided almost equally between male and female sexes. The mean age of 
patients in all groups was 52.18 ± 1.33 years, mean ulcer duration was 1.41 ± 0.36 years, and 
mean ulcer size at baseline was 2.64 ± 0.50 cm
2
 (Table 1). There were no dropouts in the 
study. All included patients completed the study protocol.  
The mean percentage of ulcer healing per week in groups 2 and 3 is shown in Figure 
1. The healing percentage increased each week in all groups. At the end of the study, mean 
reduction in ulcer size and depth was 1.70 ± 1.05cm
2
 and 0.35 ± 0.14 cm
2













and 0.25 ± 0.11 cm
2
, and 2.84 ± 1.67 cm
2
 and 0.27 ± 0.15 cm
2
 in groups 1, 2, and 3, 
respectively (Table 2). 
The clinical improvement in the ulcers at the end of the study is shown in Table 3. 
The numbers of patients in whom ulcers were improved (ulcer size was smaller at the end of 
the study compared with that at baseline), persisted (ulcer size remained the same at the end 
of the study), and worsened (ulcer size was larger at the end of the study) are shown in Figure 
2. In this study, the percentage of improved ulcers was higher in groups 2 and 3 (22%) than in 
group 1 (21%). Clinical picture before and after application of gel in each groups shown in 
Figure 3, 4, and 5, respectively. 
No adverse events were encountered in any group. During clinical examination, no 
patient had any clinical signs of allergic contact dermatitis or infection (no erythema of the 
skin around the ulcer, no swelling, no warmth on palpation, no odor, and no exudation).  
The difference in the ulcer size before and after treatment in the three groups was 
compared using the Mann–Whitney U test. The results showed a significant difference 
among the three groups in ulcer size (p < 0.005) and depth (p < 0.005), with the best result 
occurring in group 3. 
 
Discussion 
Table 1 shows that the work risk and duration of ulcer formation were not different 
among the groups. At the end of the study, good clinical outcomes were obtained in all 
groups: 21 ulcers (98.5%) improved in group 1, 22 (100%) improved in group 3 with no 
worsening ulcers, and 22 (100%) improved in group 2. There was a trend for decreasing ulcer 
width and depth in groups 2 and 3 per week (Table 2). In the comparative test of the ulcer 
size among groups 1, 2, and 3, the mean width was significantly different (p = 0.000; p 











the beginning to the end of treatment. The results indicated that the mean weekly 
improvement in ulcer width up to the end of treatment was better in group 3 than in groups 1 
and 2, whereas the mean depth improvement did not differ among the groups.  
In dermatology, vitamin C is known as an antioxidant with a role in collagen 
synthesis. These functions are believed to be useful in wound healing. The antioxidant 
function of vitamin C is beneficial in neutralizing ROS present in chronic ulcers. Vitamin C 
also directly stimulates collagen synthesis. SAP is a stable derivative of vitamin C. Although 
this derivative has the same function as that of vitamin C, it has better stability. The use of 
vitamin C and metabolite products simultaneously is expected to accelerate wound healing, 
with faster healing times, thereby resulting in less cost and increased quality of life of patients 
[19,20,22,25–28]. 
To date, reports have discussed the effect of the mixture of hAMMSC-CM + vitamin 
E on the wound healing process, but some studies have been conducted to determine the 
effect of growth factors and vitamin E separately on wound healing; all studies have shown 
satisfactory results [23,24]. 
A randomized controlled trial was conducted by Uchi et al. [9] to evaluate the 
efficacy of a topical fibroblast growth factor (bFGF) in 150 patients with chronic 
nonischemic diabetic ulcers. The subjects were divided into placebo (n = 51), 0.001% bFGF 
(n = 49), and 0.01% bFGF (n = 49) groups and received treatment for a maximum of 8 
weeks. At the end of the study, ulcers with a wound healing area of >75% were found in 
57.5%, 72.3%, and 82.2% of the patients, respectively, with a significant difference found 
between the 0.01% bFGF and placebo groups (p = 0.025) [9]. 
The results were in accordance with those of our study. The anti-inflammatory 
cytokines contained in the agents administered to groups 1 to 3 are thought to relieve tissue 











walking. The levels of pro-inflammatory cytokines and increasing protease in chronic 
wounds cause the wound to remain in a prolonged inflammatory phase. A high protease 
enzyme will decrease the local growth factor production, and therefore, the wound will not 
enter the wound healing proliferation phase [29,30]. 
A study analyzing the product of mesenchymal stem cell metabolites showed that 
many mediator substances, such as growth factors, cytokines, and chemokines, that are 
essential for tissue repair can be found in the tissue medium of mesenchymal stem cell 
metabolites, particularly vascular endothelial growth factor, platelet-derived growth factor, 
basic fibroblast growth factor, epidermal growth factor, keratinocyte growth factor, and 
transforming growth factor-fi (TGF-p). Applications of a topical metabolite stem cell product 
can overcome a prolonged inflammatory phase in chronic wounds because it contains anti-
inflammatory cytokines and growth factors; thus, the inflammatory phase can be resolved, 
and the wound can enter the healing proliferation and remodeling phase [12,13]. 
Fiori et al. [10] compared the rate of ulcer healing in the fingers of patients with 
systemic sclerosis. One group received standard ulcer treatment plus vitamin E gel 
application, and one group only received standard care procedures. The healing time and 
resolution of pain were faster in the group receiving vitamin E gel compared with those in the 
control group (p < 0.0001) [10]. Chronic ulcers showed increasing levels of ROS or free 
radicals, which could delay the wound healing process and inhibit formation of granulation 
tissue and epithelialization. Vitamin E is an antioxidant that can reduce damage caused by 
free radicals released by neutrophils in the inflammatory phase of the wound healing process 
[3,5]. In addition to its antioxidant activity, vitamin E has anti-inflammatory and anti-
aggregating properties and can cause vasodilation of small blood vessels. The level of 
vitamin E (α-tocopherol) in hAMMSC-CM + vitamin E gel is thought to reduce free radicals, 











granulation and re-epithelialization tissue that assisted in the ulcer healing process in this 
study [24].
 
Table 2 shows the comparison of ulcer size before and after overall treatment in each group. 
There was a significant decrease in the ulcer width and depth: 1.70 ± 1.05 cm
2
, p = 0.000 in 
group 1, 2.84 ± 1.67 cm
2
, p = 0.000 in group 3, and 2.01 ± 1.19 cm
2
, p = 0.000 in group 2. 
Reduced volume or depth of a wound was demonstrated by the proliferation of 
granulation tissue. Wound contraction was caused by granulation of the 
fibroblast/myofibroblast at the base of the wound. The degree of contraction and re-
epithelialization in the chronic wound healing process was highly dependent on the anatomic 
location and was not associated with the cause. Ligament retainers in loose tissue, such as the 
back, abdomen, or face, were more loose and rarer; thus, wound contraction had a major role 
in the healing process. Tightly adherent tissue, such as that in the palms, soles of the feet, or 
anterior tibial region, has a dense and firm skin ligament, and therefore the process of wound 
contraction was less important. The wound healing process in these areas was more 
dependent on epithelialization. An ulcer on the plantar pedis has a larger surface epithelial 
area to be closed by re-epithelialization compared with the depth of the ulcer through 
formation of granulation tissue. This was because the wound on the sole of the foot did not 
contract, and thus there was only a small amount of granulation tissue underlying the ulcer 
surface. This caused no significant difference in the mean ulcer depth before and after 
treatment among all groups [26,27]. 
The present study has a few limitations. We did not conduct off-loading, i.e., reducing 
or removing the load on the legs. Off-loading can be conducted via bed rest or via the use of 
crutches, wheelchairs, walkers, and special footwear [16]. The pressure on the plantar pedis 
in people with neuropathy should be distributed evenly to avoid high pressure in certain areas 











to reduce standing or walking activities, but this was very difficult to implement because 
most subjects had to work to fulfill their daily needs. Another limitation was that there was 
no subject grouping based on the location of the ulcer and anatomical structure. Because 
ulcer healing is influenced by the amount of pressure obtained during standing and walking, 
the location of the ulcer and its anatomical structure has an important role. Ulcers located on 
the protrusion of the bone (the soles of the front legs, the soles of the hind legs) experience 
higher pressure than those on the middle palm when standing or walking. 
 
Conclusion 
The hAMMSC-CM + vitamin E gel clinically and statistically decreased the mean ulcer 
width more significantly than hAMMSC-CM only and hAMMSC-CM + vitamin C, but there 
was no difference in the mean ulcer depth in all groups. All gels have been proven to 
decrease the size of chronic plantar of leprosy ulcers by increasing the mean healing of the 
ulcer width and depth every week until week 8, but the process was larger and faster in group 
3. There were no complications or side effects due to gels in any subject. Further 
experimental analytic research in randomized controlled clinical trials should be conducted to 
compare effects of the gel on healing of CPUL with off-loading in the form of a foot board 
specifically designed to help reduce stress and repetitive mechanical stress, which can affect 
the healing process. In addition, further studies should apply additional criteria in selecting a 
good match between the groups (matching) according to the location of the ulcer and 
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Group 3  
(n = 22) 
Group 1  
(n = 22) 
Group 2  
(n = 22) 
Sex 
 Male, n (%) 











 21–50 years, n (%) 











 Requires long standing/walking, n (%) 










Duration of ulcer (years) 
 <1 year, n (%) 
 1–5 years, n (%) 
























Table 2. Percentage of reduction of ulcers 
 Group 1 (n = 22) Group 2 C (n = 22) Group 3 (n = 22) 
The mean size of the ulcer ± 
SD 
- Week I ± SD 
- Week II ± SD 
- Week III ± SD 
- Week IV ± SD 
- Week V ± SD 
- Week VI ± SD 
- Week VII ± SD 




1.08 ± 0.59 
1.31 ± 0.74 
1.48 ± 0.86 
1.59 ± 0.94 
1.65 ± 0.97 
1.68 ± 1.03 
1.70 ± 1.05 
 
 
0.32 ± 0.47 
0.79 ± 0.63 
1.18 ± 0.75 
1.44 ± 0.92 
1.65 ± 0.95 
1.75 ± 0.99 
1.88 ± 1.04 
2.01 ± 1.19 
 
 
0.47 ± 0.59 
1.01 ± 0.69 
1.67 ± 1.35 
2.19 ± 1.52 
2.48 ± 1.59 
2.64 ± 1.64 
2.73 ± 1.67 
2.84 ± 1.67 
The mean depth of the ulcer 
± SD 
- Week I ± SD 
- Week II ± SD 
- Week III ± SD 
- Week IV ± SD 
- Week V ± SD 
- Week VI ± SD 
- Week VII ± SD 




0.15 ± 0.11 
0.21 ± 0.14 
0.26 ± 0.15 
0.30 ± 0.16 
0.32 ± 0.15 
0.33 ± 0.15 
0.34 ± 0.15 
0.35 ± 0.14 
 
 
0.04 ± 0.05 
0.09 ± 0.09 
0.15 ± 0.11 
0.19 ± 0.10 
0.21 ± 0.09 
0.24 ± 0.11 
0.24 ± 0.11 




0.05 ± 0.07 
0.09 ± 0.08 
0.14 ± 0.11 
0.18 ± 0.13 
0.23 ± 0.14 
0.25 ± 0.14 
0.26 ± 0.14 












Table 3. Clinical improvement of the ulcers at the end of the study 
Improvement of ulcers at the 
end of the study 
Group 1 (n = 22)  Group 2 (n = 22) Group 3 (n = 
22) 
Improved, n (%) 
Persisted, n (%) 












Figure 1. The mean percentage of size reduction in ulcers every week in the three groups 
hAMMSC-CM: human amniotic membrane-mesenchymal stem cell-conditioned medium 
Figure 2. Clinical improvement of the ulcers at the end of the study 
Figure 3. (A) Chronic ulcer before application in group 1. (B) Recovered ulcer at week 2 
after gel application. 
Figure 4. (C) Chronic ulcer before gel application in group 3. (D) Recovered ulcer at week 2 
after gel application. 
Figure 5. (E) Chronic ulcer before gel application in group 2. (F) Recovered ulcer at week 4 
after gel application. 
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